HDAC3 synergizes with MYCN to repress Grainyhead-like 1 (GRHL1) gene transcription, and GRHL1 overexpression inhibits the proliferation and in vivo growth of MNA-NB, suggesting that GRHL1 is a potential therapeutic target for HDAC inhibitors vorinostat (SAHA) or panobinostat (LBH589) (Fabian et al., 2014). The gene discussed is HDAC9; the disease is neuroblastoma.